{"brief_title": "Phase II Pilot Study of Aminoimidazole Carboxamide Riboside (AICAR), a Precursor of Purine Synthesis, for Lesch-Nyhan Disease", "brief_summary": "OBJECTIVES: I. Determine the effects of aminoimidazole carboxamide riboside (AICAR) on hematologic manifestations of Lesch-Nyhan disease. II. Assess the behavioral and neurological benefits of AICAR in patients with Lesch-Nyhan disease. III. Examine the effect of AICAR on purine production.", "detailed_description": "PROTOCOL OUTLINE: After a 3-day baseline, patients are treated with aminoimidazole carboxamide riboside (AICAR) by continuous infusion for 12 days. Concurrent allopurinol and folate are allowed.", "condition": "Lesch-Nyhan Syndrome", "intervention_type": "Drug", "intervention_name": "aminomidazole carboxamide riboside", "criteria": "PROTOCOL ENTRY CRITERIA: --Disease Characteristics-- Men with Lesch-Nyhan syndrome Moderate erythrocyte macrocytosis No active urinary tract disease or impaired renal function", "gender": "Male", "minimum_age": "N/A", "maximum_age": "N/A", "healthy_volunteers": "No", "id": "NCT00004314.xml"}